Fresenius Medical Care AG Q4 FY2024 earnings call

• Executed strategic plan with significant progress, including FME25 transformation program achieving incremental sustainable savings ahead of plan, raising total savings target to EUR750 million by end of 2025.
• Implemented portfolio optimization plan, divested non-core and lower margin assets, with EUR750 million in cash proceeds from divestitures by end of 2024.
• Achieved strong patient satisfaction with Net Promoter Score of 72. U.S. care delivery saw positive same market treatment growth, and FDA approval of high-volume Hemodiafiltration-capable 5008X machine.
• Proposed dividend increase of 21% and a dividend of €1.44, with leverage ratio improving to 2.9 times and investment grade ratings from S&P, Moody's, and Fitch.

Care Delivery: In the fourth quarter, revenue increased by 3% on an outlook base, with organic growth accelerating to 6% in the quarter. In the U.S., organic growth was 7% driven by growth in value-based care, higher treatment volumes (underlying same market treatment growth of 0.5%), and improved rates and payor mix. International contributed 4% organic growth. Operating income increased by 10 percentage points, margin was 10.7%. Care Enablement: Revenue grew by 10% on an outlook range, with 10% organic growth. Operating income grew more than six-fold, and margin improved to 7.8%.

• 2025 revenue outlook assumes positive to low single-digit percent growth, including 1% headwind from portfolio optimization. Revenue from value-based care business expected to increase to around EUR1.9 billion.
• Operating income expected high teens to high 20s percent growth, implying margin of 11%-12% in 2025, tightening midterm range to 10%-14%. Expect both segments to progress within their margin target bands.
• Anticipates incremental EUR180 million FME25 savings, net labor headwind of EUR150 million to EUR200 million, and cost inflation of EUR100 million to EUR150 million.

• Risks from safe harbor statements and SEC filings, including uncertainties in geopolitical challenges and natural disasters impacting operations.
• Potential impact of ACA insurance subsidies ending in December 2024 on payor mix.
• Uncertainty in tariffs and their impact on the business, though currently estimated to be very limited.

Q: On margins, how are segment margins expected in 2025 and phasing?

A: Helen Giza stated they are not guiding to segment margins for 2025 but expect both segments to move along margin bands, with Care Enablement showing strong improvement in Q4.

Q: Does guidance include contribution from 5008x launch?

A: Martin Fischer said the 5008x launch in 2025 is too early to impact guidance, with full commercial launch in 2026.

Q: Impact of excess mortality rate?

A: Helen Giza said excess mortality was still elevated with a slight improvement in H2, and they expect a similar rate in 2025.

Q: Phasing of margin or EBIT contribution in 2025?

A: Helen Giza mentioned Q1 is traditionally weaker but no specific phasing details provided beyond that.

Q: Components of FME25 additional savings and phasing?

A: Martin Fischer said the savings are from more efficient functions (about 50%), Care Enablement manufacturing optimization, logistics, supply chain, and care delivery clinic network, with phasing to be detailed at Capital Markets Day.

Q: Labor and cost inflation details?

A: Helen Giza said there's a net 3% labor cost headwind, with normalized headcount and managing wage inflation.

Q: Debt maturity and capital allocation?

A: Martin Fischer said EUR500 million debt matures in 2025 and EUR1.9 billion in 2026, with capital allocation to be detailed at Capital Markets Day.

Q: Evolution of FME25 savings?

A: Helen Giza said the program evolved due to deeper execution, efficiency in processes, and reorientation of the company, with incremental improvements continuing.

Q: Importance of 5008x for volumes?

A: Helen Giza said 5008x and HDF treatment have shown 23% improvement in all-cause mortality in Europe, expecting similar impact in U.S. to drive volume growth.

Q: Market share gain in fourth quarter and 2025?

A: Helen Giza said they are gaining market share due to improved processes, accepted referrals, and disaster management, expecting to continue gaining in 2025.